Everyone’s experience of MS is different. People have different symptoms. Some have more relapses or their MS progresses faster. Recent research suggests these differences are influenced by more things than we thought.

Clinical trials are key to finding treatments to slow or stop progression for everyone with MS. We often focus on the drugs being tested, but it’s all the people involved who really make them happen.

Professor Alan Thompson is consultant neurologist at University College London, and past scientific chair of the International Progressive MS Alliance. He’s been researching progressive MS for 40 years. We asked him what’s changed and what’s coming next.

You may have seen stories in the papers today about a link between how much sleep you get as a teenager, and your risk of MS. We look behind the headlines to see what the research can tell us.

In this instalment of #BehindTheTrials, meet some of the people working on StarMS.

We spoke to Professor Denise Fitzgerald to find out how treatments are chosen for Octopus, our revolutionary mega-trial.

This morning, the ECTRIMS research conference hosted a Hot Topics session on lifestyle and MS. Professor Ulrik Dalgas talked about exercise and MS. 

Discover some of 2021's highlights with a festive poem from Catherine, our Research Communications Manager. 

Certain DMTs may affect the way your immune system responds to the vaccines. Professor David Baker is a neuroimmunologist from Queen Mary University of London. He’s been keeping track of new results from researchers around the world.

Max Parmar is Professor of Medical Statistics and Epidemiology at University College London. An expert in clinical trials, he has made countless contributions to medical research. Now he’s turned his attention to MS.